Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorRibeiro Lima, Marcelo
dc.contributor.authorReyes Garau, Diana
dc.contributor.authorArmengol, Marc
dc.contributor.authorFernández Serrano, Miranda
dc.contributor.authorRoue, Gael
dc.date.accessioned2020-09-14T10:28:32Z
dc.date.available2020-09-14T10:28:32Z
dc.date.issued2019-10-16
dc.identifier.citationRibeiro ML, Reyes-Garau D, Armengol M, Fernández-Serrano M, Roué G. Recent advances in the targeting of epigenetic regulators in b-cell non-Hodgkin lymphoma. Front Genet. 2019 Oct 16;10:986.
dc.identifier.issn1664-8021
dc.identifier.urihttp://hdl.handle.net/11351/5256
dc.descriptionB-cell lymphoma; DNMT; EZH2
dc.description.abstractIn the last 10 years, major advances have been made in the diagnosis and development of selective therapies for several blood cancers, including B-cell non-Hodgkin lymphoma (B-NHL), a heterogeneous group of malignancies arising from the mature B lymphocyte compartment. However, most of these entities remain incurable and current treatments are associated with variable efficacy, several adverse events, and frequent relapses. Thus, new diagnostic paradigms and novel therapeutic options are required to improve the prognosis of patients with B-NHL. With the recent deciphering of the mutational landscapes of B-cell disorders by high-throughput sequencing, it came out that different epigenetic deregulations might drive and/or promote B lymphomagenesis. Consistently, over the last decade, numerous epigenetic drugs (or epidrugs) have emerged in the clinical management of B-NHL patients. In this review, we will present an overview of the most relevant epidrugs tested and/or used so far for the treatment of different subtypes of B-NHL, from first-generation epigenetic therapies like histone acetyl transferases (HDACs) or DNA-methyl transferases (DNMTs) inhibitors to new agents showing selectivity for proteins that are mutated, translocated, and/or overexpressed in these diseases, including EZH2, BET, and PRMT. We will dissect the mechanisms of action of these epigenetic inhibitors, as well as the molecular processes underlying their lack of efficacy in refractory patients. This review will also provide a summary of the latest strategies being employed in preclinical and clinical settings, and will point out the most promising lines of investigation in the field.
dc.language.isoeng
dc.publisherFrontiers Media
dc.relation.ispartofseriesFrontiers in Genetics;10
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectCèl·lules B - Tumors
dc.subjectGenètica - Tècnica
dc.subjectEpigenètica
dc.subject.meshLymphoma, B-Cell
dc.subject.meshHigh-Throughput Nucleotide Sequencing
dc.subject.meshEpigenesis, Genetic
dc.subject.mesh/drug therapy
dc.titleRecent advances in the targeting of epigenetic regulators in b-cell non- Hodgkin lymphoma
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3389/fgene.2019.00986
dc.subject.decslinfoma de células B
dc.subject.decssecuenciación de nucleótidos de alto rendimiento
dc.subject.decsepigénesis genética
dc.subject.decs/tratamiento farmacológico
dc.relation.publishversionhttps://www.frontiersin.org/articles/10.3389/fgene.2019.00986/full
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.authoraffiliation[Ribeiro ML] Laboratory of Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain. Laboratory of Immunopharmacology and Molecular Biology, Sao Francisco University Medical School, Braganca Paulista, Brazil. [Reyes-Garau D, Armengol D, Fernández-Serrano M, Roué G] Laboratory of Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain
dc.identifier.pmid31681423
dc.identifier.wos000497436600001
dc.relation.projectidinfo:eu-repo/grantAgreement/ES/PE2013-2016/PI15%2F00102
dc.relation.projectidinfo:eu-repo/grantAgreement/ES/PE2017-2020/PI18%2F01383
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record